The company is a VIB spin-off focussing on Charcot-Marie-tooth disease and chemotherapy-induced peripheral neuropathy.
Augustine is a drug discovery and development company building a portfolio of first-in-class drugs rooted in the research on Ludo van Den Bosch at the VIB/KU Leuven Institute, Center for Brain and Disease Research.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze